ERBB2 and breast cancer: [Poly (I:C)] has been shown to have direct apoptotic and growth inhibitory effects on various human cancer cell lines [18,19], and, furthermore, is capable of augmenting the anti-tumour effects of ErbB2 antibodies for breast cancer cell lines through a putative ADCC mechanism [20].